Feasibility and Initial Results: Fluciclovine PET/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.

Fluciclovine PET real-time ultrasound fusion guidance for biopsy in post-non-prostatectomy patients with biochemical failure is feasible and identifies more recurrent prostate cancer with fewer cores compared with template biopsy in the same patient. Further study is required to determine in what manner targeted biopsy may augment template biopsy for recurrent prostate cancer.